Is there an evaluation at the end of the course?

To validate the achievement of the learning objectives, a final evaluation in the form of true/false questions is required. It must be completed in order to obtain the certificate of completion. In addition, an optional self-assessment is offered at the beginning and end of the course, allowing you to measure your progress on the targeted skills.

I have a disability. Can I receive specific support?

Yes! This training is offered as a pre-recorded video format, without subtitles. If you have a disability, we can provide an adapted alternative (technical assistance for viewing or individual supervision). For any request, please contact our disability coordinator at the following address: contact@asadis.net

How long do I have access to the course?

After your registration, the course is accessible anytime and from anywhere with unlimited access.

When does the course start?

That is entirely up to you! When you buy a course, you'll receive an access link that you can activate when you want.

Is there a student rate?

Yes there is! Learn more and request your student discount at https://asadis.net/en/student-discount/

Course: Integrating psychedelic medicines into psychotherapy

Name: Best practices for integrating psychedelic medicines into psychotherapy
Price: 120.00 USD
Availability: InStock
Rating: 91 (1 reviews)

Overview

The last thirty years of pharmaceutical research have been underwhelming, showing only slight improvements, low effectiveness, high rates of relapse and significant side effects. In contrast, psychedelic-assisted psychotherapies are at the forefront of numerous high-quality studies, yielding very promising results and low side effects.

This immersive online course provides mental health professionals with foundational knowledge and practical skills for psychedelic harm reduction and integration therapies focused on patient safety, ethical care, and optimal outcomes.

Through interactive video lessons, case studies, and downloadable resources, you will learn protocols and best practices for therapies utilizing psilocybin, MDMA, and ketamine. Course modules define mechanisms of action, recent clinical research, traditional ceremonial uses, principles of psychedelic harm reduction, techniques for helping clients prepare for sessions, integration methods for lasting benefits, and recommendations for advancing the field.

Clinicians completing this course can knowledgeably advise prospective patients on benefits versus risks and screen for contraindications. By internalizing ethical questions around treatment planning, informed consent, scope of practice, and more through real-world examples, therapists can confidently offer psychedelic harm reduction and integration therapies aligned with patient values and professional codes of conduct.

As access expands, professionals with expertise in these innovative interventions will be uniquely equipped to provide inclusive, specialized support to help individuals overcome PTSD, depression, end-of-life distress, and more. Enroll now to bring psychedelic care into your practice skillfully!

Lastly, a clarification: this course does not endorse the use of illegal drugs in clinical practice. Instead, it focuses on expanding our understanding of substances that many of our clients are already using and preparing for the emergence of a new field of practice, as many of these substances may become legal in the future.

Download the program

3h of continuing education
23 lessons that last from 5 to 15 minutes each
1 certificate of achievement
1 PowerPoint
1 bibliography
1 course evaluation
7-day money back guarantee
Unlimited access
91% of participants who completed the satisfaction survey declare they would recommend this course to a colleague

Accreditation

Ordre des Psychologues du Québec

Canadian Psychological Association

Canadian Counselling and Psychotherapy Association

Collège des médecins du Québec

For physicians who practice psychotherapy, training recognized by the Ordre des psychologues du Québec is automatically considered as activities adopted by the Collège des médecins, in accordance with Article 3 of the Regulation.

For physicians who do not practice psychotherapy, the College evaluates each recognition request based on the following criteria:

the relevance of the activity to the practice of the profession
the skills and experience of the trainer
the quality of the content and its adequacy with the physician's practice
the pedagogical framework of the activity
the quality of the documentation provided
compliance with the training objectives set out in the regulation
the presence of a certificate of participation or an evaluation

About the expert

Dr. Peter Addy, psychotherapist, is a licensed professional counselor who provides psychedelic integration and harm reduction therapy at his private practice while training psilocybin facilitators in Oregon’s approved program. After conducting psychedelic research at Yale School of Medicine and co-founding the Yale Psychedelic Science Group, he transitioned into clinical practice. Grounding his work in principles of harm reduction and transpersonal psychology, Dr. Addy skillfully supports clients who use psychedelics. His therapy and teaching approach encourages dismantling systems of oppression and inspiring radical compassion. Passionate about equitable access, he wants to empower all people to explore their inner worlds safely.

More →

Learning objectives

Define key terminology related to psychedelic medicines, including mechanisms of action for psychedelics, entheogens, empathogens, and psychoplastogens.
Assess the benefits and risks of psilocybin, MDMA, and ketamine-assisted therapies.
Apply preparation, intention setting, and integration techniques to provide psychedelic harm reduction aligned with ethical guidelines and scope of practice.
Examine strategies to improve access, education, and service quality of psychedelic-assisted therapies for patients and clinicians.

Learning material

A theoretical course illustrated with clinical examples. This course is composed of videos of 5 to 15 minutes each. The PowerPoint of the course to download.

Syllabus

PowerPoint
1. Presentation
Psychedelics Introduction
2. Definition of Key Terms
3. What are Psychedelics
Background on Psychedelic Renaissance
4. Legal Status and Access in Canada
5. Promising Clinical Applications
6. Psilocybin Recent Clinical Research
7. MDMA Recently Completed Research
8. Ketamine Recent Clinical Research
9. Indigenous Use- How they Work in Culture
10. Principles of Psychedelic Harm Reduction
11. Relative and Specific Risks
Preparation and Intention Setting
12. What is transpersonal psychology
13. How Does Spirituality Function within your Client
14. Intention Setting
15. Integration Techniques
16. Evidence-Based Clinical Skills for Better Treatment
Considerations for your Practice
17. The Different Roles
18. Ethical Considerations
19. Real Life Clinical Case Example 1
20. Real Life Clinical Case Example 2
21. Real Life Clinical Case Example 3
22. Future Directions
23. Conclusion
Bibliography

CE Credits

Download a certificate of successful completion.

Audience

This training is intended for mental health professionals.

Your comments

"Course was very interesting and informative problem. I believe us as a therapist is understanding how to deal with some of the issues that he presented, and he being a specialist could perhaps come up with the best practises for these type of situations instead of saying well, what would you do, especially if we’re not an expert in this area there is lies the disappointment in this course"
A psychologist (Canada)

Registration

$120.00 - Individual price Group price

Download the program

3h of continuing education
23 lessons that last from 5 to 15 minutes each
1 certificate of achievement
1 PowerPoint
1 bibliography
1 course evaluation
7-day money back guarantee
Unlimited access

Ask a question

Do you have a question? Then email us at contact@asadis.net

Frequently asked questions

Is there an evaluation at the end of the course?

To validate the achievement of the learning objectives, a final evaluation in the form of true/false questions is required. It must be completed in order to obtain the certificate of completion.

In addition, an optional self-assessment is offered at the beginning and end of the course, allowing you to measure your progress on the targeted skills.

These evaluations are not graded and are intended primarily to support your professional reflection.
How long do I have access to the course?

After your registration, the course is accessible anytime and from anywhere with unlimited access.
When does the course start?

That is entirely up to you! When you buy a course, you'll receive an access link that you can activate when you want.
Is there a student rate?

Yes there is! Learn more and request your student discount.

You may also be interested in:

Mindfulness-integrated Cognitive Behaviour Therapy: A transdiagnostic approach for crisis intervention, chronic conditions and relapse prevention

Dr. Bruno Cayoun, Psychologist

Understanding Psychiatric Medications: What Every Therapist Should Know

Dr. Kenneth Carter, Psychologist

Working with Attachment Style in Psychotherapy

Dr. Gail Myhr, Associate professor of psychiatry

Legal notice

The courses offered by ASADIS are accredited by different professional organisations. In addition, ASADIS is approved by the Canadian Psychological Association to offer continuing education for psychologists. ASADIS maintains responsibility for the program.

The CPA’s approval of an individual, group, or organization as a CE Sponsor or Provider is restricted to the activities described in the approved application or annual report form. The CPA’s approval does not extend to any other CE activity the Sponsor or Provider might offer. In granting its approval, the CPA assumes no legal or financial obligations to Sponsors, Providers, or to those individuals who might participate in a Sponsor or Provider’s CE activities or programs. Further, responsibility for the content, provision, and delivery of any CE activity approved by the CPA remains that of the CE Sponsor or Provider. The CPA disclaims all legal liability associated with the content, provision, and delivery of the approved CE activity.

Best practices for integrating psychedelic medicines into psychotherapy

Dr. Peter Addy, Psychotherapist